What is Dianthus Therapeutics's G&A?

Dianthus Therapeutics (DNTH) reported G&A of $12.47M in Q1 2026.

How has Dianthus Therapeutics's G&A changed year-over-year?

Dianthus Therapeutics's G&A increased by 69.9% year-over-year, from $7.34M to $12.47M.

What is the long-term trend for Dianthus Therapeutics's G&A?

Over 3 years (2021 to 2024), Dianthus Therapeutics's G&A has grown at a -3.6% compound annual growth rate (CAGR), from $27.93M to $24.99M.

Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.

Dianthus Therapeutics DNTH G&A

G&A at other companies

Spyre Therapeutics, Inc.SYRE

$15.23M+27.5%

Kymera TherapeuticsKYMR

$20.36M+25.1%

Protagonist TherapeuticsPTGX

$13.28M+13.1%

Immunovant, Inc.IMVT

$17.27M-14.4%

Segments

By product

See full

Share Based Compensation Expense$5.75M—

Personnel And Related Costs$4.06M+58.6%

Other Costs$2.65M+37.0%

Other financials

Income statement

See full

Revenue$396.0K-81.8%

Operating income-$46.5M-40.3%

Net income-$40.8M-38.4%

EPS (diluted)-$0.85-3.7%

Balance sheet

See full

Cash & equivalents$627.7M+6,105%

Total debt$1.4M-2.3%

Total equity$1.2B+266%

Total assets$1.2B+258%

Cash flow

See full

Operating cash flow-$28.9M-4.4%

CapEx$10.0K-58.3%

Free cash flow-$28.9M-4.4%

Valuation

See full

Market cap$4.51B+662%

Profitability

See full

Operating margin-4,558.4%-9,354pp

Net margin-4,104.8%-7,304pp

FCF margin-3,561.6%-6,956pp

Returns & leverage

See full

Return on equity-28.6%+3.2pp

Debt / equity0×0.0×

Current ratio29.3×+13.3×

Where this comes from

Reported directly by Dianthus Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.

The official record: Dianthus Therapeutics’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Dianthus Therapeutics's g&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Dianthus Therapeutics's G&A?: Dianthus Therapeutics (DNTH) reported G&A of $12.47M in Q1 2026.
How has Dianthus Therapeutics's G&A changed year-over-year?: Dianthus Therapeutics's G&A increased by 69.9% year-over-year, from $7.34M to $12.47M.
What is the long-term trend for Dianthus Therapeutics's G&A?: Over 3 years (2021 to 2024), Dianthus Therapeutics's G&A has grown at a -3.6% compound annual growth rate (CAGR), from $27.93M to $24.99M.
What does G&A mean?: Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.